The Effect of Platelet-rich Plasma in Patients With Osteoarthritis of the Knee
Launched by ROYAN INSTITUTE · Aug 19, 2013
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
In this study all eligible patients (Based on the inclusion and exclusion criteria) were randomly allocated into two study groups by a Stratified Permuted Block randomization method: group A received platelet rich plasma, group B (control group) received only placebo.
All of the patients underwent a standard long protocol for knee osteoarthritis. All patients with grade II,III and IV of radiographic knee OA are selected. On average, in each instance, the amount of platelets in the peripheral blood is 4 to 6 times the baseline level.
Group A: 1-3 cc injection of placebo Group B: 1-3 cc inj...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 to 65 years
- • 2. Body mass index (BMI) ≤33 kg/m2
- • 3. Grade 2And above imaging of osteoarthritis
- • 4. History of knee pain or swelling should have at least 4 months
- Exclusion Criteria:
- • 1. treated with steroids and Anti-coagulant or anti-platelet aggregation
- • 2. history of infectious, systemic diseases, Immune deficiency and coagulation disorders
- • 3. Patients with Hb ≤11, Plt ≤ 150000
- • 4. Varus \> 10 , valgus \> 10
About Royan Institute
The Royan Institute is a leading research organization dedicated to advancing the fields of reproductive health, stem cell biology, and regenerative medicine. Established to promote scientific innovation and clinical applications, the Institute focuses on translating cutting-edge research into therapeutic solutions. With a strong commitment to ethical practices and collaboration, Royan Institute conducts rigorous clinical trials aimed at improving patient outcomes and enhancing healthcare practices globally. Through its multidisciplinary approach and state-of-the-art facilities, the Institute strives to push the boundaries of medical science and contribute significantly to the understanding and treatment of complex health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Hamid Gourabi, PhD
Study Chair
Head of Royan Institute
Nasser Aghdami, MD,PhD
Study Director
Head of Department of Regenerative Medicine Of Royan Institute & cell therapy center
Mohsen Emadedin, MD
Study Director
Orthoped scientist in Royan Institute
Ali Mirazimi Bafghi, MD
Principal Investigator
Regenerative Medicine Department of Royan Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials